Skip to main content
Erschienen in: World Journal of Surgery 2/2018

13.11.2017 | Original Scientific Report

Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience

verfasst von: Francesca Torresan, Elisabetta Cavedon, Caterina Mian, Maurizio Iacobone

Erschienen in: World Journal of Surgery | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Medullary thyroid carcinoma (MTC) is a rare C cells-derived tumor, with a hardly predictable long-term prognosis. This study was aimed to evaluate the predictive factors of cure and survival after surgery for MTC in a monocentric series.

Methods

A retrospective analysis of the long-term outcomes was assessed in 255 MTC patients operated between 1980 and 2015 at Padua University hospital.

Results

Sporadic MTC occurred in 65.1% and hereditary MTC in 34.9% of patients. At a median follow-up of 93 months (range 7–430), the cure rate was 56.8%. The overall 10-year survival was 84.4%, and MTC-related death rate was 15.3%. Patients who died because of MTC had a median age of 61 years (range 21–84) and were at stages III–IV in all cases; deaths occurred in 18% of sporadic MTC, 6% of MEN2a and 66.7% of MEN2b patients. None of the patients at stages I–II died because of the disease, but 17.7% had persistent/recurrent disease. Based on univariate analysis, age, gender, genetic variant, extent and year of surgery, tumor size, lymph-nodal metastases and tumor stage significantly affected cure and survival rates. At multivariate analysis, only patient- and tumor-related features (age, lymph-nodal status and stage) remained significant independent prognostic factors.

Conclusions

Radical surgery is the only chance of definitive cure in MTC, but it is possible only at early stage; in advanced stages, even extensive surgery could not grant cure and prolonged survival. Stage, nodal metastases and age remain the main predictive factors for cure and survival.
Literatur
1.
Zurück zum Zitat Pacini F, Castagna MG, Cipri C et al (2015) Medullary thyroid carcinoma. Clin Oncol 22:475–485CrossRef Pacini F, Castagna MG, Cipri C et al (2015) Medullary thyroid carcinoma. Clin Oncol 22:475–485CrossRef
2.
Zurück zum Zitat Wells SA, Asa SL, Dralle H et al (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610CrossRefPubMedPubMedCentral Wells SA, Asa SL, Dralle H et al (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Kebebew E, Greenspan FS, Clark OH et al (2005) Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 200:890–896CrossRefPubMed Kebebew E, Greenspan FS, Clark OH et al (2005) Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 200:890–896CrossRefPubMed
4.
Zurück zum Zitat Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 48:265–273CrossRef Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 48:265–273CrossRef
5.
Zurück zum Zitat Dottorini ME, Assi A, Sironi M et al (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565CrossRefPubMed Dottorini ME, Assi A, Sironi M et al (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565CrossRefPubMed
6.
Zurück zum Zitat Raue F, Kotzerke J, Reinwein D et al (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig 71:7–12CrossRefPubMed Raue F, Kotzerke J, Reinwein D et al (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig 71:7–12CrossRefPubMed
7.
Zurück zum Zitat Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134–2142CrossRefPubMed Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134–2142CrossRefPubMed
8.
Zurück zum Zitat Siironen P, Hagström J, Mäenpää HO et al (2016) Lymph node metastases and elevated postoperative calcitonin: predictors of poor survival in medullary thyroid carcinoma. Acta Oncol 55:357–364CrossRefPubMed Siironen P, Hagström J, Mäenpää HO et al (2016) Lymph node metastases and elevated postoperative calcitonin: predictors of poor survival in medullary thyroid carcinoma. Acta Oncol 55:357–364CrossRefPubMed
9.
Zurück zum Zitat AJCC (2017) AJCC cancer staging manuals, 8th edn. Springer, Berlin, pp 52–53 AJCC (2017) AJCC cancer staging manuals, 8th edn. Springer, Berlin, pp 52–53
10.
Zurück zum Zitat Leboulleux S, Baudin E, Travagli JP et al (2004) Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299–310CrossRef Leboulleux S, Baudin E, Travagli JP et al (2004) Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299–310CrossRef
11.
Zurück zum Zitat Machens A, Dralle H (2016) Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 175:219–228CrossRefPubMed Machens A, Dralle H (2016) Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 175:219–228CrossRefPubMed
13.
Zurück zum Zitat De Groot JWB, Plukker JTM, Wolffenbuttel BHR et al (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 65:729–736CrossRef De Groot JWB, Plukker JTM, Wolffenbuttel BHR et al (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 65:729–736CrossRef
14.
15.
Zurück zum Zitat Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821CrossRefPubMed Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821CrossRefPubMed
16.
Zurück zum Zitat Abraham DT, Low T-H, Messina M et al (2011) Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann Surg Oncol 18:219–225CrossRefPubMed Abraham DT, Low T-H, Messina M et al (2011) Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann Surg Oncol 18:219–225CrossRefPubMed
17.
Zurück zum Zitat Rendl G, Manzl M, Hitzl W et al (2008) Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 69:497–505CrossRef Rendl G, Manzl M, Hitzl W et al (2008) Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 69:497–505CrossRef
18.
Zurück zum Zitat Kebebew E, Ituarte PHG, Siperstein AE et al (2000) Medullary thyroid carcinoma clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139–1148CrossRefPubMed Kebebew E, Ituarte PHG, Siperstein AE et al (2000) Medullary thyroid carcinoma clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139–1148CrossRefPubMed
19.
Zurück zum Zitat Mirallié E, Iacobone M, Sebag F et al (2004) Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol 30:790–795CrossRefPubMed Mirallié E, Iacobone M, Sebag F et al (2004) Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol 30:790–795CrossRefPubMed
20.
Zurück zum Zitat Brauckhoff M, Machens A, Lorenz K et al (2014) Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B. Ann Surg 259:800–806CrossRefPubMed Brauckhoff M, Machens A, Lorenz K et al (2014) Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B. Ann Surg 259:800–806CrossRefPubMed
21.
Zurück zum Zitat Pelizzo MR, Torresan F, Nacamulli D et al (2015) Early, prophylactic thyroidectomy in hereditary medullary thyroid carcinoma: a 26-year monoinstitutional experience. Am J Clin Oncol 38:508–513CrossRefPubMed Pelizzo MR, Torresan F, Nacamulli D et al (2015) Early, prophylactic thyroidectomy in hereditary medullary thyroid carcinoma: a 26-year monoinstitutional experience. Am J Clin Oncol 38:508–513CrossRefPubMed
22.
Zurück zum Zitat Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687CrossRefPubMed Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687CrossRefPubMed
23.
Zurück zum Zitat Mian C, Pennelli G, Barollo S et al (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 164:971–976CrossRefPubMed Mian C, Pennelli G, Barollo S et al (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 164:971–976CrossRefPubMed
24.
Zurück zum Zitat Romei C, Ugolini C, Cosci B et al (2012) Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 22:476–481CrossRefPubMed Romei C, Ugolini C, Cosci B et al (2012) Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 22:476–481CrossRefPubMed
25.
Zurück zum Zitat Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655–2663CrossRefPubMed Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655–2663CrossRefPubMed
27.
Zurück zum Zitat Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95:586–591CrossRefPubMed Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95:586–591CrossRefPubMed
28.
Zurück zum Zitat Franc S, Niccoli-Sire P, Cohen R et al (2001) Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 55:403–409CrossRef Franc S, Niccoli-Sire P, Cohen R et al (2001) Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 55:403–409CrossRef
29.
Zurück zum Zitat Tamagnini P, Iacobone M, Sebag F, Marcy M, De Micco C, Henry JF (2005) Lymph node involvement in macroscopic medullary thyroid carcinoma. Br J Surg 92(4):449–453CrossRefPubMed Tamagnini P, Iacobone M, Sebag F, Marcy M, De Micco C, Henry JF (2005) Lymph node involvement in macroscopic medullary thyroid carcinoma. Br J Surg 92(4):449–453CrossRefPubMed
30.
Zurück zum Zitat Machens A, Dralle H (2013) Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 257:323–329CrossRefPubMed Machens A, Dralle H (2013) Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 257:323–329CrossRefPubMed
31.
Zurück zum Zitat Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803CrossRefPubMed Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803CrossRefPubMed
32.
Zurück zum Zitat Elisei R, Bottici V, Luchetti F et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168CrossRefPubMed Elisei R, Bottici V, Luchetti F et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168CrossRefPubMed
33.
Zurück zum Zitat Costante G, Meringolo D, Durante C et al (2007) Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 92:450–455CrossRefPubMed Costante G, Meringolo D, Durante C et al (2007) Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 92:450–455CrossRefPubMed
Metadaten
Titel
Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience
verfasst von
Francesca Torresan
Elisabetta Cavedon
Caterina Mian
Maurizio Iacobone
Publikationsdatum
13.11.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 2/2018
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4321-z

Weitere Artikel der Ausgabe 2/2018

World Journal of Surgery 2/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.